Good News! CE Mark Approval for Bioperfectus Monkeypox Virus Real Time PCR Kit

Company news
2022-05-24

Shanghai, China, 25th May 2022—We Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) solemnly announce that we have received CE mark approval for Monkeypox Virus Real Time PCR Kit. With CE mark approval, Bioperfectus Monkeypox Virus Real Time PCR Kit is now available for the European Union and other countries and regions in recognition of CE certification as monkeypox virus threats are still mounting in many non-endemic countries.

 

According to WHO, polymerase chain reaction (PCR) is the preferred laboratory test given its accuracy and sensitivity. The Bioperfectus Monkeypox Virus Real Time PCR Kit is based on real-time PCR technology. Specific primers and probes are designed based on F3L gene areas of the Monkeypox virus. In addition, the kit also contains a housekeeping gene (RNase P) as an internal control (IC) for specimen sampling and nucleic acid extraction.

 

As an essential addition to Bioperfectus Total PCR Solution, Bioperfectus Monkey Virus Real Time PCR Kit applies to Bioperfectus Nucleic Acid Extraction Solution, Bioperfectus STC-96A, STC-96A PLUS Real-Time PCR System, and other primary PCR instruments in the market.

 

At the same time, Bioperfectus Monkeypox Virus Real Time PCR Kit can also detect veterinary samples with an exogenous internal control. For more information, please get in touch with your sales representative via info@bioperfectus.com.

 

 

About Bioperfectus

Bioperfectus, a public listed company on Shanghai Stock Exchange (SSE:688399), has been one of the leading molecular diagnostic solution providers specializing in infectious diseases ever since 2010. With headquarters located in Jiangsu, subsidiaries in Shanghai, Beijing, Xi'an, Taizhou, Hainan, and Yinchuan. Bioperfectus is pioneering in the molecular diagnostics market with our products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests, and automation laboratory devices. Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream of creating a healthier future for our next generations. For more information, please follow us on LinkedIn or visit www.bioperfectus.com.

 

Reference

 

MOST READ

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14

Clinical Validation of Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit

Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) applied for the clinical evaluation in XYZ Laboratory (XYZ Laboratory 2009 Ranch Rd. 620 N, STE 325, Austin, TX 78732, USA), a CAP accredited CLIA certified high complexity clinical molecular diagnostic laboratory to perform and report the Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit.

2022-11-07

The COVID-19 is Delaying the Cervical Cancer Screening

Human papillomavirus (HPV) is the primary cause of cervical cancer, which is preventable through screening and early treatment. The elimination of cervical cancer has been defined by the WHO as achieving an incidence rate below 4 cases per 100,000 women per year since 2020.

2022-10-25